Guideline recommendations on the use of dual antiplatelet therapy (DAPT) in patients with
acute coronary syndromes and in those undergoing percutaneous coronary intervention …

Heart failure is a syndrome with a pathophysiological basis that can be traced to dysfunction
in several interconnected molecular pathways. Identification of biomarkers of heart failure …

The recommendations listed in this CPG are, whenever possible, evidence based. An
extensive evidence review was conducted through October 2012, and other selected …

Zachęca się pracowników opieki zdrowotnej, aby w pełni uwzględniali te wytyczne
ESC/EACTS, gdy dokonują oceny klinicznej, a także kiedy określają i realizują medyczne …

The task of developing ESC/EACTS Guidelines covers not only the integration of the most
recent research, but also the creation of educational tools and implementation programmes …

Optimizing outcomes after percutaneous coronary intervention (PCI) requires balancing
between the risks of thrombotic and bleeding events in individual patients. 1–3 However …

Background: Immature platelets are less responsive to the effects of antiplatelet drugs and
contain messenger ribonucleic acid that is translationally active. They can be measured …

Current challenges exist to widespread clinical implementation of genomic medicine and
pharmacogenetics. The University of Florida (UF) Health Personalized Medicine Program …

Background: The choice of antiplatelet therapy after acute coronary syndrome (ACS) is
complicated: Ticagrelor and prasugrel are novel alternatives to clopidogrel, patients with …

Objectives: This study sought to evaluate the impact of treatment with prasugrel and high-
dose clopidogrel on the basis of platelet function testing in patients with acute coronary …